33 results about "Eukaryotic translation" patented technology

A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5″ position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I:

or a pharmaceutically acceptable salt thereof, wherein R₁ is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.

The invention belongs to the technical field of photodynamic gene therapy, particularly relating to a photosensitizer binding protein and polypeptide and application thereof. In the invention, the photosensitizer binding protein is screened from a human liver cDNA (complementary Deoxyribonucleic Acid) phage display library. The binding protein is a human eukaryotic translation elongation factor (eEF1A1) protein and a protein molecule which is 70 to 80 percent similar to the protein in protein structure; the photosensitizer binding polypeptide is eEF1A1 C terminal 25aa and polypeptide which is70 to 80 percent similar to the 25aa in amino acid sequence. The photosensitizer binding protein can be bound with a porphyrin type photosensitizer in vitro and has an effect of enriching the porphyrin type photosensitizer in vivo; photosensitizer binding protein genes are transfected to various mammalian cells through adenoviruses, slow viruses or other modes; and a better photodynamic therapy effect is produced after artificial adjustment and control over inducible expression. In addition, the photosensitizer binding protein and polypeptide (PSP) provide a valuable reference for developing a photosensitizer prodrug and designing the specifically targeted photosensitizer.

Methods, compositions and kits for treating proliferative and non-proliferative diseases associated with abnormal protein synthesis. Chimeric peptide constructs are comprised in compositions and kits for use in the treatment of proliferative diseases, such as ovarian cancer, and for inhibiting protein synthesis in a tumor cell compared to a non-tumor cell.

The present application relates to papaya plants having increased resistance to the papaya ringspot virus as compared to a wild type plant due to a mutation in the eukaryotic translation initiation factor 4e and/or eukaryotic translation initiation factor iso4e gene leading to non-functional eukaryotic translation initiation factor 4e and/or eukaryotic translation initiation factor iso4e proteins. Methods of producing such papaya plants having increased resistance to the papaya ringspot virus are described.

Bacterial packaging strains useful for generating recombinant double-stranded RNA nucleocapsids (rdsRNs) are provided. The packaging strains are useful for the production of RNA encoding vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Recombinant ssRNA is introduced into the strains and packaged to form rdsRNs de novo. The packaging strains and rdsRNs may also comprise nucleic acid sequences that stabilize a closed loop eukaryotic translation complex; nucleic acid sequences encoding one or more proteins that interfere with a host cell type I interferon (IFN) response; as well as recombinant alphavirus replicons encoding a protein complex specific for plus strand RNA-dependent synthesis of minus strand RNA

The invention provides a method for preparing a recombinant eukaryotic mRNA molecule by using a prokaryotic transcription system. The method comprises the following steps: 1) expressing an enzyme system required for the transcription and capping process of the recombinant eukaryotic mRNA, and obtaining a prokaryotic in-vitro transcription-capping enzyme system; 2) preparing a linear transcriptiontemplate DNA; and 3) transcribing, capping and purifying the recombinant mRNA. The recombinant mRNA molecule prepared by the method provided by the invention has all mRNA characteristics required by eukaryotic organisms in the protein translation process, so that the recombinant mRNA molecule can be further identified and utilized by a eukaryotic translation system. The method provided by the invention overcomes the defects in the field of recombinant mRNA at present, can produce the recombinant eukaryotic mRNA with stable genetic characteristics and no carrier inhibition effect in a simple process and at low cost, and meets the large-scale industrial production demand.

A screening method for identifying compounds that alter the fidelity with which the initiation codon in mRNAs is recognized by the translational apparatus in eukaryotes is disclosed. This screening method was used to identify compounds having such activity. Methods of altering the fidelity of initiation codon selection are also disclosed. Methods of treating disorders characterized by single nucleotide mutations in initiation codons using compounds identified by the screening method, as well as methods of treating fungal and parasitic infections and hyperproliferative disorders using compounds identified by the screening method are also disclosed.

Provided are an autoantibody specifically binding to an exosomal protein EIF3A (Eukaryotic translation initiation factor 3 subunit A) or a fragment including an antigen-binding site (paratope) thereof, a hybridoma cell line producing the autoantibody, a polypeptide having an amino acid sequence of an antigenic determinant (epitope) specifically binding to the autoantibody, a composition for diagnosing liver cancer including an agent measuring an expression level of the autoantibody or the fragment including the antigen-binding site thereof, a kit for diagnosing liver cancer including the composition, and a method of providing information for diagnosis of liver cancer by using the composition. Further, provided is a method of screening for a therapeutic agent for liver cancer by using an expression level of the autoantibody. When anti-EIF3A autoantibody of the present invention is used as a diagnostic marker for liver cancer, the incidence of liver cancer may be diagnosed at a high level only by using non-invasive biological samples. Furthermore, liver cancer may be easily diagnosed by using only the amino acid sequence identified in the present invention, leading to the effective development of diagnostic products such as a diagnostic kit for liver cancer.

The invention discloses miRNA related to woody plant ammonium nitrogen response and application thereof, the miRNA comprises miRNA, the miRNA is miRNA (pc-miR166b) with up-regulated expression in a woody plant root system under an ammonium nitrogen treatment condition, a target gene of the miRNA is an eukaryotic translation initiation factor (eIF), the miRNA is highly expressed in an ammonium nitrogen treatment process, and by down-regulating the expression of the target gene, the response of the ammonium nitrogen in the woody plant can be reduced, so that the response of the ammonium nitrogen in the woody plant can be reduced, and the response of the ammonium nitrogen in the woody plant can be reduced. The miRNA (pc-miR166b) participates in the response process of the root system of the woody plant to the ammonium nitrogen, the miRNA (pc-miR166b) has good correlation with the response process of the root system of the woody plant to the ammonium nitrogen, and the effectiveness and molecular biology verification shows that the expression quantity of the pc-miR166b has obvious difference between the ammonium nitrogen treatment sample and the control group treatment sample; the method is of great significance to cultivation of novel woody plant germplasm capable of efficiently absorbing and utilizing soil nitrogen, and is suitable for popularization and application.

The invention belongs to the technical field of microorganisms, and particularly relates to a construction method of a monascus purpureus YJX-8 cDNA library and application of the library to screening of ester synthase LIP05 interaction protein. According to the construction method of the monascus purpureus YJX-8 cDNA library disclosed by the invention, LIP05 interaction proteins, namely cell nucleic acid binding proteins and eukaryotic translation initiation factors, are obtained by screening the library constructed according to the method, and expression of the LIP05 can be regulated and controlled on transcription and translation levels. The cDNA library constructed by the invention has an application prospect and a practical value for screening interaction proteins.

The present invention relates to a method of diagnosing bladder cancer in an individual. Further, the present invention relates to a method of determining the course of bladder cancer in an individual. Furthermore, the present invention relates to a kit for diagnosing bladder cancer in an individual or determining the course of bladder cancer in an individual.

The invention discloses a phosphorylated EIF5B specific antibody and a preparation method and application thereof. The antibody is a human-derived phosphorylated ElF5BT78 specific site polyclonal antibody. On one hand, the antibody provides possibility for detecting expression of a phosphorylated EIF5BT78 site and verifying a related molecular mechanism; and on the other hand, the antibody is combined with phosphorylated eukaryotic translation initiation factor 5B (p-EIF5B) protein. The invention further provides a composition containing the antibody. The specific phosphorylated EIF5BT78 site polyclonal antibody is constructed by utilizing an existing phosphorylated protein antibody technology, the problems that in the prior art, EIF5B phosphorylated antibodies are few in variety and poor in specificity are solved, and possibility is provided for detecting expression of the phosphorylated EIF5BT78 site and verifying the related molecular mechanism.